Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

RECRUITING

NCT07713485

PHASE1

Study of XmAb412 in Healthy Participants

Sponsor: Xencor, Inc.

View on ClinicalTrials.gov

Summary

This Phase 1 Study will evaluate the safety, tolerability, pharmacokinectics and pharmacodynamics of XmAb412 in healthy adult participants

Official title: A Phase 1, First-in-human, Randomized, Double-blind, Placebo-controlled, Single and Multiple-dose Escalation Trial to Evaluate Safety, Tolerability, and Pharmacokinetics of XmAb412 in Healthy Adult Participants

Key Details

Gender

All

Age Range

18 Years - 55 Years

Study Type

INTERVENTIONAL

Enrollment

128

Start Date

2026-07-13

Completion Date

2028-03

Last Updated

2026-07-20

Healthy Volunteers

Yes

Conditions

Not Applicable - Healthy Adult Participants

Interventions

DRUG

XmAb412 Monoclonal Bispecific Antibody

Monoclonal Bispecific Antibody

DRUG

Placebo

Locations (2)

Xencor Investigative Site

Joondalup, Western Australia, Australia